| 9.54 -0.05 (-0.52%) | 11-12 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 16.65 | 1-year : | 20.34 |
| Resists | First : | 14.26 | Second : | 17.42 |
| Pivot price | 11.82  |
|||
| Supports | First : | 9.14 | Second : | 7.61 |
| MAs | MA(5) : | 9.54  |
MA(20) : | 12.16 |
| MA(100) : | 18.2 |
MA(250) : | 19.84 |
|
| MACD | MACD : | -1.8 |
Signal : | -1.6 |
| %K %D | K(14,3) : | 7 |
D(3) : | 6.8 |
| RSI | RSI(14): 26.5 |
|||
| 52-week | High : | 25.59 | Low : | 9.14 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SNDX ] has closed above bottom band by 22.5%. Bollinger Bands are 95.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 9.94 - 9.99 | 9.99 - 10.04 |
| Low: | 9.2 - 9.25 | 9.25 - 9.3 |
| Close: | 9.46 - 9.55 | 9.55 - 9.61 |
Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.
Thu, 12 Nov 2026
SNDX: Maintenance growth and frontline trials support a new phase of pipeline expansion - TradingView
Thu, 12 Nov 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Syndax Pharmaceuticals, Inc.- SNDX - PR Newswire
Mon, 09 Nov 2026
Syndax Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - Yahoo Finance
Sat, 07 Nov 2026
Syndax Pharmaceuticals, Inc. (SNDX) Seasonal Returns Chart - Yahoo Finance - Yahoo! Finance Canada
Thu, 05 Nov 2026
Why Is Syndax Pharmaceuticals (SNDX) Drawing So Much ASH 2026 Attention? - Yahoo Finance
Thu, 05 Nov 2026
Syndax Pharmaceuticals Inc (SNDX) (Q3 2026) Earnings Call Highlights: Revenue Surges 82% as ... - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 90 (M) |
| Shares Float | 81 (M) |
| Held by Insiders | 1.6 (%) |
| Held by Institutions | 125.5 (%) |
| Shares Short | 18,000 (K) |
| Shares Short P.Month | 20,660 (K) |
| EPS | -2.37 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.19 |
| Profit Margin | -72.4 % |
| Operating Margin | -50.3 % |
| Return on Assets (ttm) | -18 % |
| Return on Equity (ttm) | -426.5 % |
| Qtrly Rev. Growth | 81.5 % |
| Gross Profit (p.s.) | -0.07 |
| Sales Per Share | 3.21 |
| EBITDA (p.s.) | -1.99 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -177 (M) |
| Levered Free Cash Flow | -113 (M) |
| PE Ratio | -4.03 |
| PEG Ratio | 0 |
| Price to Book value | -50.22 |
| Price to Sales | 2.96 |
| Price to Cash Flow | -4.85 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|